Myelofibrosis - Pipeline Review, H2 2015

Date: September 30, 2015
Pages: 189
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M1A04F46632EN
Leaflet:

Download PDF Leaflet

Myelofibrosis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Myelofibrosis - Pipeline Review, H2 2015’, provides an overview of the Myelofibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Myelofibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Myelofibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Myelofibrosis Overview
Therapeutics Development
Pipeline Products for Myelofibrosis - Overview
Pipeline Products for Myelofibrosis - Comparative Analysis
Myelofibrosis - Therapeutics under Development by Companies
Myelofibrosis - Therapeutics under Investigation by Universities/Institutes
Myelofibrosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Myelofibrosis - Products under Development by Companies
Myelofibrosis - Products under Investigation by Universities/Institutes
Myelofibrosis - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CTI BioPharma Corp.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
Johnson & Johnson
JW Pharmaceutical Corporation
KaloBios Pharmaceuticals, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
Onconova Therapeutics, Inc.
Pfizer Inc.
PharmaEssentia Corporation
Promedior, Inc.
Stemline Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Myelofibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-911543 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CWP-291 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evofosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glasdegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hu8F4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imetelstat sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-39110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KB-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCL-161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pixantrone dimaleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pomalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRM-151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ropeginterferon ALFA-2B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sotatercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myelofibrosis - Recent Pipeline Updates
Myelofibrosis - Dormant Projects
Myelofibrosis - Discontinued Products
Myelofibrosis - Product Development Milestones
Featured News & Press Releases
Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
Jun 12, 2015: Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
Jun 12, 2015: Promedior Presents Additional Positive Phase 2 Data for PRM-151 in Myelofibrosis at EHA Annual Meeting
Jun 10, 2015: CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
Jun 04, 2015: Promedior Announces Presentation of Additional Positive Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of the European Hematology Association
May 30, 2015: Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
May 14, 2015: Baxter BioScience to Present New Data at ASCO On Pacritinib from Expanding Oncology Pipeline Designed to Address Unmet Needs in Challenging Cancers
Apr 27, 2015: Geron to Present at the Bank of America Merrill Lynch Healthcare Conference
Apr 22, 2015: CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
Mar 16, 2015: CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Myelofibrosis, H2 2015
Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Myelofibrosis - Pipeline by Acceleron Pharma, Inc., H2 2015
Myelofibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Myelofibrosis - Pipeline by Celgene Corporation, H2 2015
Myelofibrosis - Pipeline by CTI BioPharma Corp., H2 2015
Myelofibrosis - Pipeline by Galena Biopharma, Inc., H2 2015
Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2015
Myelofibrosis - Pipeline by Incyte Corporation, H2 2015
Myelofibrosis - Pipeline by Italfarmaco S.p.A., H2 2015
Myelofibrosis - Pipeline by Johnson & Johnson, H2 2015
Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H2 2015
Myelofibrosis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015
Myelofibrosis - Pipeline by Novartis AG, H2 2015
Myelofibrosis - Pipeline by Onconova Therapeutics, Inc., H2 2015
Myelofibrosis - Pipeline by Pfizer Inc., H2 2015
Myelofibrosis - Pipeline by PharmaEssentia Corporation, H2 2015
Myelofibrosis - Pipeline by Promedior, Inc., H2 2015
Myelofibrosis - Pipeline by Stemline Therapeutics, Inc., H2 2015
Myelofibrosis - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Myelofibrosis Therapeutics - Recent Pipeline Updates, H2 2015
Myelofibrosis - Dormant Projects, H2 2015
Myelofibrosis - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Myelofibrosis, H2 2015
Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Acceleron Pharma, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CTI BioPharma Corp.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
Johnson & Johnson
JW Pharmaceutical Corporation
KaloBios Pharmaceuticals, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
Onconova Therapeutics, Inc.
Pfizer Inc.
PharmaEssentia Corporation
Promedior, Inc.
Stemline Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Skip to top


Myelofibrosis - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 175 pages
Endometriosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 132 pages
Mitochondrial Diseases - Pipeline Review, H1 2014 US$ 1,500.00 May, 2014 · 50 pages

Ask Your Question

Myelofibrosis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: